We’ve talked previously about bioethanol and its impact on health. According to Juan Enriquez, Chairman and CEO of Biotechonomy, a life sciences research and investment firm, and a member of the management team at Synthetic Genomics, a company dedicated to commercializing synthetic genomic processes and naturally occurring processes for alternative energy solutions, bioethanol is not bioenergy.
QuitWinLive – The Great American Smokeout
Today, the American Cancer Society (ACS) celebrates the Great American Smokeout, an annual event in the U.S. to encourage Americans to quit smoking. According to the U.S. Centers for Disease Control and Prevention (CDC), in 2006 one in five U.S. adults smoked [1]. The Great American Smokeout challenges those people to smoke less or quit smoking for the day. The event also raises awareness of the many effective ways to quit for good.
The ACS has just wrapped up their first ever video contest on YouTube, where they asked people to create videos – one minute or less – to discourage smoking. You can check out the contest winners at the American Cancer Society.
You can also read more about the harmful effects of smoking and tobacco smoke in these articles here at Highlight HEALTH:
- Smoking Duration vs. Intensity and the Impact on Lung Cancer Risk
- Irreversible Gene Expression Changes From Smoking
- Smoking Cessation Timeline: What Happens When You Quit
- Second-hand Smoke Exposure Linked to Psychological Problems in Children
Accept the Great American Smokeout Challenge.
Quit for one day, or quit for good.
References
-
Cigarette smoking among adults–United States, 2006. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61.
View abstract
Merck HIV Vaccine Increases Risk of HIV Infection
Merck has been testing a candidate HIV vaccine in two large phase II clinical trials; the STEP study in North and South America, the Caribbean and Australia, and a parallel study called Phambili in South Africa.
STEP was a multi-center, randomized, double-blind, placebo-controlled phase II test-of-concept clinical trial. Started in December 2004, enrollment in the study was completed by March 2007 and more than 2,500 participants had received all three doses of vaccine or placebo. STEP was evaluating two primary efficacy endpoints:
- Whether the vaccine prevented HIV infection in subjects who were HIV negative at the beginning of the study.
- Whether the vaccine lowered the amount of virus in subjects who became HIV infected during the course of the study.
However, last month the drug trial was halted because the vaccine appeared to be increasing the risk of HIV infection among study participants. The South African study Phambili, which began in 2007 using the same vaccine has been halted [1].
Elsevier’s Approaches to Public Access of Biomedical and Cancer Research
Elsevier, a leading publisher of over 400 medical and scientific journals serving more than 30 million scientists, students and health and information professionals worldwide, has initiated a beta test program called Patient Research. The program gives patients, family members and caregivers access to medical articles to help them understand their health issues.